C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart F—Production and Process Controls

21 C.F.R. § 211.110 (2026)

Sampling and testing of in-process materials and drug products

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1993–2019 8citing cases
At a glance

Courts have cited this section in 8 opinions since 1993. The most litigated part is subsection (a) (1 case).

(a) To assure batch uniformity and integrity of drug products, written procedures shall be established and followed that describe the in-process controls, and tests, or examinations to be conducted on appropriate samples of in-process materials of each batch. Such control procedures shall be established to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product. Such control procedures shall include, but are not limited to, the following, where appropriate:

(1) Tablet or capsule weight variation;

(2) Disintegration time;

(3) Adequacy of mixing to assure uniformity and homogeneity;

(4) Dissolution time and rate;

(5) Clarity, completeness, or pH of solutions.

(6) Bioburden testing.

(b) Valid in-process specifications for such characteristics shall be consistent with drug product final specifications and shall be derived from previous acceptable process average and process variability estimates where possible and determined by the application of suitable statistical procedures where appropriate. Examination and testing of samples shall assure that the drug product and in-process material conform to specifications.

(c) In-process materials shall be tested for identity, strength, quality, and purity as appropriate, and approved or rejected by the quality control unit, during the production process, e.g., at commencement or completion of significant phases or after storage for long periods.

(d) Rejected in-process materials shall be identified and controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.

[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]
The 8 cases that cite 21 C.F.R. § 211.110 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).
cites § 211.110 3×subsections: (a)cited by 13 cases
Summary
No passage or summary on file for this case yet.
2
GREENSupernus Pharm., Inc. v. TWi Pharm., Inc., 265 F. Supp. 3d 490 (D.N.J. 2017).
cites § 211.110 2×cited by 4 cases
Where it cites § 211.110
“See 21 C.F.R. § 211.110 . These controls are required to ^assure batch- uniformity and integrity of drug products.”
3
GREENCrocker v. Kv Pharm. Co., 782 F. Supp. 2d 760 (E.D. Mo. 2010).
cites § 211.110 1×cited by 12 cases
Where it cites § 211.110
“Failure to establish control procedures to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug market, as required by 21 C.F.R. § 211.110 (a); c. Failure to make…”
Later courts cite it for
“had knowledge of or participated in underlying fiduciary breaches.” · 2 citing courts
4
GREENUnited States v. Jay Marcus, 82 F.3d 606 (4th Cir. 1996).
cites § 211.110 1×cited by 20 cases
Where it cites § 211.110
“See 21 C.F.R. § 211.110 (a)(4) (1995). 2 . When submitting an abbreviated new drug application seeking FDA approval to market a generic drug, an applicant must demonstrate, inter alia, that the drug formulation that it proposes to use is bioequivalent to the name-brand drug.”
Later courts cite it for
“a determi- nation of the amount of loss suffered focuses, as it does in theft cases, on the value of the money, property, or services unlawfully taken.” · 2 citing courts
5
GREENIn re Terazosin Hydrochloride Antitrust Litig., 164 F. Supp. 2d 1340 (S.D. Fla. 2000).
cites § 211.110 1×cited by 13 cases
Where it cites § 211.110
“21, 2000; see also 21 C.F.R. § 211.110 ; (Geneva Opp’n, Ex. 3, at 3 (Aff.”
Later courts cite it for
“part of a larger scheme to restrain the domestic sale of generic tera-zosin hydrochloride products.” · 2 citing courts
6
REDPub. Pension Fund Grp. v. Kv Pharm. Co., 705 F. Supp. 2d 1088 (E.D. Mo. 2010).
cites § 211.110 1×cited by 4 cases
Reversed in part by Public Pension Fund Group v. KV PHARMACEUTICAL CO. (2012): the Court of Appeals for the Eighth Circuit's own opinion in this case ("Ill For the reasons stated, we affirm in part, reverse in part, and remand to…
Where it cites § 211.110
“Failure to establish control procedures to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug market, as required by 21 C.F.R. § 211.110 (a); C. Failure to make…”
7
NO FLAGIn re Genentech, Inc., 367 F. Supp. 3d 1274 (N.D. Okla. 2019).
cites § 211.110 2×cited by 0 cases
Where it cites § 211.110
“See also 21 C.F.R. § 211.110 (a)( ), (b) (referencing "in-process specifications" applicable to drug product "weight variation"); Ex.”
8
GREENUnited States v. Marcus, No. 95-5600 (4th Cir. May 3, 1996).
cites § 211.110 1×cited by 0 cases
Where it cites § 211.110
“See 21 C.F.R. § 211.110 (a)(4) (1995). 2 Marcus was not initially aware of the modification, but when he learned of it, he elected not to inform the FDA or to seek approval for the revision for fear that the FDA would consider the change to be significant and require additional…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320062019

One bar per year. Tallest: 2 cases in 1996. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
4th Cir.2E.D. Mo.2D.N.J.2S.D. Fla.1N.D. Okla.1
By subsection
(a)1 case
United States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com